Transplant-Ineligible Myeloma: Can Daratumumab + Bortezomib Maintenance Improve Outcomes? | #IMS26

Esteban Tamariz-Amador, MD, of Clínica Universidad de Navarra discusses treatment for transplant-ineligible myeloma patients at IMS 2026 in Glasgow. He shares three-year results from a Spanish Myeloma Group study that added a monthly two-drug maintenance after daratumumab-based Dara-VMP treatment. Viewers will learn that, compared with historical results, fewer patients progressed despite an older, frailer group, and why avoiding long-term lenalidomide may help some older patients stay on treatment.

If this video has helped you or a loved one, consider donating to HealthTree. Every donation helps us continue to create free and high-quality blood cancer educational content: https://give.healthtree.org/give/628617/src=htu

For an organized lesson structure, watch on our site here: https://linktr.ee/HealthTreeUniversity
Create a free account to track your progress, bookmark lessons, and keep up-to-date on the latest advancements in treating cancer!

Patients have the key to find cures for cancer. Learn more about HealthTree's services here: https://healthtree.org/curehub?utm_source=social+media&utm_medium=htu+youtube&utm_campaign=htu-curehub&utm_content=general
Educated and empowered patients have better outcomes. We've partnered with hundreds of medical experts and doctors to help you learn more about your disease.

Timestamps:
0:00 Introduction: Dr. Esteban Tamariz-Amador, Clínica Universidad de Navarra
0:14 Treating Transplant-Ineligible Myeloma: The Challenge
0:26 ALCYONE and MAIA: Two Landmark Trials
0:50 Why Maintenance May Explain the Difference
1:13 The Spanish Myeloma Group's OPTIMAL Study
1:38 Three-Year Results: Fewer Patients Progressed
2:23 Why Bortezomib and Daratumumab Instead of Lenalidomide?